Comparison Chart Cellectar Biosciences, Inc.

CLRB

US15117F8804

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	CELLECTAR BIOSCIENCES, INC.	Other Pharmaceuticals	+1.23%	+10.27%	-58.14%	-65.60%	-99.53%	11.53M

Real-time Estimate Cboe BZX 11:25:10 2026-10-26 EDT			5-day change	1st Jan Change
1.260 ^USD	+3.28%		+10.27%	-58.14%

10-15	Cellectar Biosciences, Inc. Presents Efficacy Results From Phase 2b CLOVER WaM Subset Analysis Of Iopofosine I 131 In Patients Relapsed/Refractory To BTK Inhibitor Therapy	CI
09-29	Cellectar Biosciences Announces Subset Analysis of Data from Phase 2 Clover Wam Clinical Trial of iopofosine I 131 in Patients Refractory or Resistant to BTK Inhibitor Therapy	CI

Comparison Chart Cellectar Biosciences, Inc.

Stocks

CLRB

US15117F8804

Pharmaceuticals

Compared values